Related Experiment Video
Updated: May 20, 2025
Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
Published on: April 12, 2024
One-Year Results of 0.01% and 0.05% Atropine Eye Drops in Childhood Myopia Progression
Insights
Low-dose atropine eye drops (0.01%) effectively slow myopia progression in children. This treatment was better tolerated than higher concentrations, showing fewer side effects for myopia control.
Area of Science:
- Ophthalmology
- Pediatric Medicine
- Pharmacology
Background:
- Myopia, or nearsightedness, is a growing global health concern in children.
- Effective myopia control strategies are crucial to prevent associated long-term ocular health risks.
Purpose of the Study:
- To compare the efficacy and tolerability of 0.01% and 0.05% atropine eye drops for slowing myopia progression in children.
- To evaluate the impact of every-other-day atropine treatment on refractive error and axial length.
Main Methods:
- A retrospective study included children aged 5-15 years with myopia (-1.00 to -8.00 D) and significant recent progression.
- Participants received either 0.01% or 0.05% atropine eye drops every other day.
- Ophthalmic examinations included cycloplegic refraction, axial length (AL) measurement, and pupil size assessment.
Main Results:
- Both 0.01% and 0.05% atropine significantly slowed myopia progression over 12 months (P < .001).
- Axial length changes were not significantly different between the groups (P = .52).
- The 0.01% atropine group reported no photophobia or blurred near vision, while the 0.05% group experienced these side effects in 12.5% and 33% of cases, respectively.
Conclusions:
- Every-other-day use of both 0.01% and 0.05% atropine eye drops is effective in slowing myopia progression in children.
- 0.01% atropine demonstrates superior tolerability compared to 0.05% atropine, with a significantly lower incidence of adverse effects like photophobia and blurred vision.
Purpose:
To compare 0.01% and 0.05% atropine eye drops with every other day treatment for slowing myopia progression in children.
Methods:
Children aged 5 to 15 years who had myopia of -1.00 to 8.00 diopters (D), astigmatism less than -2.50 D, and myopic progression of at least 1.00 D in the past year were included in the retrospective study. The 0.01% and 0.05% atropine eye drops were applied every other day. At each visit, all patients underwent complete ophthalmic examination including cycloplegic refraction, axial length (AL), and photopic-mesopic pupil sizes. Spherical equivalent (SE), AL, and photopicmesopic pupil sizes were evaluated.
Results:
In total, 92 eyes of 46 patients were included in the study (22 in the 0.01% atropine group and 24 in the 0.05% atropine group). At the end of the 12-month follow-up period, the mean SE changes were -0.41 ± 0.28 and -0.19 ± 0.22 D in the 0.01% and 0.05% atropine groups, respectively (P < .001). The AL changes were 0.19 ± 0.16 and 0.16 ± 024 mm in the 0.01% and 0.05% atropine groups, respectively (P = .52). Side effects such as photophobia and blurred near vision were not observed in the 0.01% atropine group, but in the 0.05% atropine group, photophobia was observed in 3(12.5%) cases and blurred near vision was observed in 8 (33%) cases.
Conclusions:
The 0.01% and 0.05% atropine eye drops significantly slowed the progression of myopia with every other day use. The 0.01% atropine was better tolerated than 0.05% atropine. [J Pediatr Ophthalmol Strabismus. 2025;62(4):297-302.].
More Related Videos
06:19Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
05:56Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment